Arcus BiosciencesRCUS
Market Cap: $1.53B
About: Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Employees: 577
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
95% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 22
55% more call options, than puts
Call options by funds: $3.58M | Put options by funds: $2.31M
12% more funds holding
Funds holding: 170 [Q1] → 191 (+21) [Q2]
2% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 62
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
1.9% less ownership
Funds ownership: 59.02% [Q1] → 57.12% (-1.9%) [Q2]
22% less capital invested
Capital invested by funds: $1.01B [Q1] → $791M (-$221M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Wedbush Robert Driscoll 51% 1-year accuracy 30 / 59 met price target | 79%upside $30 | Outperform Reiterated | 9 Aug 2024 |
B of A Securities Jason Zemansky 80% 1-year accuracy 8 / 10 met price target | 37%upside $23 | Neutral Maintained | 9 Aug 2024 |
Barclays Peter Lawson 29% 1-year accuracy 8 / 28 met price target | 49%upside $25 | Overweight Maintained | 8 Jul 2024 |
Truist Securities Asthika Goonewardene 48% 1-year accuracy 12 / 25 met price target | 162%upside $44 | Buy Maintained | 24 Jun 2024 |
Financial journalist opinion
Based on 4 articles about RCUS published over the past 30 days